Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2/3 1Phase 2 1

Status

Recruiting 3Completed 1Active not recruiting 1

Sponsor Class

OTHER 5NIH 1NETWORK 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Breast 3Head & Neck 1Gynecologic 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sentinel Lymph Node Biopsy (SLNB) 1Mouth Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 262Specimen Handling 253pembrolizumab 230Cyclophosphamide 216Radiotherapy 204Nivolumab 168Cisplatin 161Carboplatin 145Biopsy 144Radiosurgery 128fludarabine 123Blood Specimen Collection 116Gemcitabine 111Paclitaxel 107Surveys and Questionnaires 106Standard of Care 102venetoclax 94Dexamethasone 93Bevacizumab 92Radiation 87Rituximab 81Capecitabine 80Cytarabine 79Oxaliplatin 77Drug Therapy 75Doxorubicin 75Ipilimumab 73durvalumab 70fludarabine phosphate 69atezolizumab 68

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Sentinel Lymph Node Biopsy × 90 days × Clear all
NCT02689427 2026-05-12

Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
24 enrolled 7 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07579286 2026-05-12

LumiNOde

N.N. Petrov National Medical Research Center of Oncology

Phase NA Recruiting
100 enrolled
Breast

Breast Neoplasms

NCT02564848 2026-05-11

Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Estrogen-Positive Breast Cancer Over Age 65

Cedars-Sinai Medical Center

Phase NA Active not recruiting
200 enrolled
Breast

Breast Neoplasms

NCT04333537 2026-05-04

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

NRG Oncology

Phase 2/3 Recruiting
686 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Mouth Neoplasms

NCT07508306 2026-04-02

Patent Blue SLN in Early Ovarian Cancer Prospective Study (FIGO I-II) Evaluating Patent Blue SLN Mapping. Injection Into IP/UO Ligaments in Situ. Goals: Assess Feasibility and Accuracy vs Standard Lymphadenectomy to Minimize Surgical Morbidity

Faculty of Medicine of Tunis

Recruiting
30 enrolled
Gynecologic

Sentinel Lymph Node Biopsy (SLNB)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡